Roche's Avastin remains most requested drug in UK's cancer drugs fund PMLiVE Completing the top five most requested drugs were Roche's MabThera (rituximab), which had 5.3 per cent of all requests (about 572) and GlaxoSmithKline's Tyverb (lapatinib), which had 5.2 per cent of all requests (about 561). The ten most commonly used ... |
